Pacira BioSciences (PCRX) Other Non-Current Liabilities (2010 - 2026)
Pacira BioSciences (PCRX) posted quarterly Other Non-Current Liabilities of $24.6 million for Q1 2026, up 3.12% year-over-year from $23.9 million in Q1 2025, and up 19.63% quarter-over-quarter from $20.6 million in Q4 2025.
Pacira BioSciences (PCRX) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
Pacira BioSciences' Other Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $24.6 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 3.12% year-over-year to $24.6 million; the TTM figure through Mar 2026 stood at $24.6 million (up 3.12% YoY), while the FY2025 annual figure was $20.6 million, up 22.33% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $24.6 million, up from $20.6 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $25.3 million in Q3 2025, with the low at $9.7 million in Q4 2022.
- The 5-year median for Other Non-Current Liabilities is $13.6 million (2023), against an average of $16.6 million.
- Peak annual rise in Other Non-Current Liabilities reached 153.04% in 2022, while the deepest fall reached 51.59% in 2022.
- Pacira BioSciences' Other Non-Current Liabilities stood at $9.7 million in 2022, then soared by 40.38% to $13.6 million in 2023, then increased by 23.9% to $16.8 million in 2024, then increased by 22.33% to $20.6 million in 2025, then increased by 19.63% to $24.6 million in 2026.
- Business Quant data shows PCRX's Other Non-Current Liabilities at $24.6 million in Q1 2026, $20.6 million in Q4 2025, and $25.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Pacira BioSciences | 945.31 Mn | 694.28 Mn | 148.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.65 Mn |
| Mar 31, 2026 | 24.61 Mn |
| Dec 31, 2025 | 20.57 Mn |
| Sep 30, 2025 | 25.30 Mn |
| Jun 30, 2025 | 25.15 Mn |
| Mar 31, 2025 | 23.87 Mn |
| Dec 31, 2024 | 16.82 Mn |
| Sep 30, 2024 | 12.78 Mn |
| Jun 30, 2024 | 13.01 Mn |
| Mar 31, 2024 | 12.69 Mn |
| Dec 31, 2023 | 13.57 Mn |
| Sep 30, 2023 | 11.95 Mn |
| Jun 30, 2023 | 11.78 Mn |
| Mar 31, 2023 | 11.58 Mn |
| Dec 31, 2022 | 9.67 Mn |
| Sep 30, 2022 | 19.11 Mn |
| Jun 30, 2022 | 19.47 Mn |
| Mar 31, 2022 | 10.72 Mn |
| Dec 31, 2021 | 19.97 Mn |
| Sep 30, 2021 | 7.55 Mn |